K Herrmann

Statistics

Publications

Citations

H-Index

Active since

2017

Affiliations

Bristol-Myers Squibb (Germany)(Current)

University Hospital Leipzig

K Herrmann is an author at Bristol-Myers Squibb (Germany) specializing in cost-effectiveness modeling, cost-effectiveness analysis, and cost-effectiveness comparison.

ORCID

Publications per year

2017–2023

Publications

Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands

Felix E. de Jongh, Reva Efe, K Herrmann et al. · International Journal of Breast Cancer · 2022 · 16 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +16

GRADE guidance 23: considering cost-effectiveness evidence in moving from evidence to health-related recommendations

Feng Xie, Ian Shemilt, Luke Vale et al. · Journal of Clinical Epidemiology · 2023 · 14 citations · Full text

Pharmacy, Pharmacoeconomics, Cost-effectiveness Analysis +15

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada

L. Weijers, Christoph Baerwald, Francesco Saverio Mennini et al. · Rheumatology International · 2017 · 10 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17

Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.

Aljoscha S. Neubauer, C. Minartz, K Herrmann et al. · PubMed · 2018 · 10 citations

Pharmacy, Internal Medicine, Pharmacotherapy +17

Budget impact of the Oncotype DX® test compared to other gene expression tests in patients with early breast cancer in Germany

Michael P. Lux, C. Minartz, H. Müller-Huesmann et al. · Cancer Treatment and Research Communications · 2022 · 10 citations · Full text

Pharmacy, Oncology, Pharmacoeconomics +17

1–5 of 5